Hong Kong's two-track 2026: capital flees the Hang Seng, capital piles into the asset managers

On the morning of 2 July 2026, two things happened in Hong Kong that, read in isolation, tell contradictory stories about the city's financial health. The South China Morning Post published an opinion essay arguing that Hong Kong has become "the worst-performing major stock market," a verdict now broadly accepted in regional trading rooms. Hours later, the city's Securities and Futures Commission released survey data showing that assets under management at Hong Kong-domiciled firms had climbed to a record HK$5.38 trillion. The same day, Japanese pharmaceutical giant Takeda confirmed a drug-discovery deal worth up to US$600 million with the Hong Kong-based biotech Insilico Medicine — the kind of cross-border biotech partnership the city has spent years trying to attract.

The headline-grabbing weakness is real; the underlying accumulation of capital is also real. What is unfolding is not a collapse but a reorganisation: equity listings and traded sentiment are weakening, while regulated asset management, biotech R&D and Hong Kong's role as a China-out-bound capital platform are quietly thickening. The narrative that the city is losing its financial standing deserves to be tested against the quieter numbers.

The Hang Seng problem the SCMP essay describes

The SCMP opinion essay of 2 July 2026 frames the bear case bluntly: Hong Kong has underperformed every other major index in 2026, weighed down by weak Chinese property exposure, subdued mainland retail flows, and what the piece characterises as an absence of "new narrative" catalysts that Tokyo, Seoul and Mumbai have managed to produce. The argument is not novel — Hong Kong has spent the better part of three years in a defensive crouch — but the timing matters. The Hang Seng's underperformance is now severe enough that local commentators are willing to call it structural rather than cyclical.

Two data points anchor the bear view. First, the listed index has lost ground against the Nikkei 225, the Kospi and India's Nifty 50 on a year-to-date basis through 2 July 2026, a comparison that would have read as absurd five years ago. Second, IPO volumes and secondary offerings have not recovered to the levels the city enjoyed during the 2017–2021 window. Mainland Chinese issuers that floated in Hong Kong during that era have watched their secondary-market performance lag, and several have shifted follow-on capital raises to Shanghai or Shenzhen.

The SCMP essay's structural argument runs as follows: the city's listed market is tied tightly to mainland property, mainland internet platforms and mainland banks — three sectors currently working through deleveraging, regulatory reset and weak consumer demand in China. So long as those three sectors dominate Hang Seng weightings, the index will move with the worst-performing parts of the mainland cycle. Tokyo and Seoul, by contrast, have benefited from AI-linked semiconductor earnings and a weaker local currency that has pulled foreign capital into exporters. The relative comparison is not a verdict on Hong Kong's institutional quality; it is a verdict on which sectors lead which index in 2026.

The SFC's record AUM number, and what it actually measures

The Reuters report published at 16:40 UTC on 2 July 2026 carries a different signal. According to the SFC's annual survey, Hong Kong-domiciled asset managers held a record HK$5.38 trillion (roughly US$690 billion) in assets under management as of the survey reference date, up from a year earlier. The number is, by itself, an unambiguous headline: more capital is sitting in regulated Hong Kong portfolios than at any point in the city's history.

The number does not mean "the stock market is booming." It means something narrower and structurally more important. Assets under management captures money that has been entrusted to Hong Kong-based fund managers — including private bank mandates, sovereign wealth inflows, insurance general accounts, and the offshore arms of mainland fund houses. It is, in other words, a flow number, not a price number. Capital is being routed to Hong Kong intermediaries even as the listed market drifts.

This is consistent with the SCMP essay in one respect: it suggests that the weakness is in the primary listed market specifically, not in Hong Kong's broader intermediation role. Beijing's incremental opening of cross-border wealth channels — Southbound trading, wealth-management connect schemes, family-office licences — has funnelled capital through Hong Kong vehicles without requiring it to clear the Hang Seng. The listed market is one product among many. The AUM number reflects the rest.

Takeda, Insilico and what a US$600m biotech deal signals

The Takeda–Insilico deal, reported by Nikkei Asia at 03:31 UTC on 2 July 2026, sits inside the same dual-track story. Insilico Medicine is a Hong Kong-based AI-driven drug discovery company with a research footprint in mainland China and a clinical-development operation increasingly oriented toward US and European regulators. Takeda, one of Japan's largest pharmaceutical groups, has agreed to use Insilico's platform to identify novel targets across an undisclosed number of therapeutic areas, with the headline value of up to US$600 million tied to discovery, development and regulatory milestones plus royalties.

The deal is significant for three reasons. First, it confirms that Hong Kong-headquartered biotech — the cluster the city has been incubating since the 2018 listing rule change for pre-revenue biotechs — can compete for marquee pharmaceutical partnerships against Boston, Cambridge and Basel. Second, the partner is Japanese, not American, which is consistent with the broader pattern of 2025–26: regional pharma and regional capital are tightening ties as Western large-cap pharma focuses on internal cost discipline and bolt-on acquisitions. Third, the AI-discovery layer is itself a competitive moat. Insilico's pitch to Takeda is that its generative-chemistry pipeline can compress the early discovery timeline in ways that traditional high-throughput screening cannot. Whether that pitch will hold up commercially is the multi-year question; the upfront commercial signal — a US$600m headline — is real.

Read against the SCMP essay, the Takeda deal is a small counter-data point. Read against the SFC's AUM number, it is structurally consistent: a Hong Kong-anchored, AI-enabled biotech firm that is now large enough to do platform deals with global pharma is exactly the kind of private-stage asset that flows through the city's fund managers, family offices and pre-IPO capital pools. The AUM number, in other words, is the denominator; Takeda–Insilico is one of the assets inside it.

The Polymarket moment — a cautionary aside

A separate Hong Kong story surfaced at 12:51 UTC on 2 July 2026 via Polymarket's news feed: the city's authorities are facing public backlash after an AI-generated anti-drug video circulated widely, with critics arguing the production made controlled substances look visually appealing rather than warning against them. The incident is a reminder that the city's use of AI-generated media is not limited to drug discovery and financial modelling; it is also being deployed in public communications, where errors of taste and judgement carry direct reputational cost. The backlash does not change the structural picture, but it is the kind of episode that tends to be cited later as evidence of a regulatory environment that is racing ahead of its own risk frameworks.

Counterpoint: the bear case is not a mood, it is a math problem

The honest rebuttal to the dual-track reading is that AUM and listed-market performance are not unrelated. The Hang Seng is where Hong Kong-domiciled asset managers realise gains for their underlying clients; a sustained bear market eventually drags on retail sentiment, slows mainland mandate growth, and forces private banks to defend allocations against redemption pressure. The SCMP essay is correct that there is a feedback loop, and that the listed market's weakness is not free.

The counter to that counter is that the feedback loop is slower than it once was. Hong Kong's intermediation role has been deliberately diversified — Connect schemes, family-office licences, hedge-fund domicile, private credit — so that the listed market is now one of several on-ramps, not the only one. A multi-year Hang Seng bear market will still hurt. It will not, on its own, produce the kind of structural damage the SCMP essay implies.

The structural frame, in plain prose, is this: Hong Kong is mid-transition from a listing-led financial centre to a broader intermediation platform. The transition is uncomfortable precisely because listings — the most visible, most quoted, most politically symbolic part of the business — are also the part most exposed to the mainland deleveraging cycle. Everything else is, in 2026, holding up better than the headline.

Stakes: who wins, who loses, over what horizon

If the dual-track reading holds, the winners over a three-to-five-year horizon are Hong Kong-based private bank and asset managers, family-office operators, the Hong Kong arms of mainland fund houses, and AI-enabled biotechs with credible cross-border deal flow. The losers are primary-market intermediaries — IPO sponsors, brokers whose revenue is dominated by equity underwriting, and the small cohort of mainland issuers who still see Hong Kong as the only offshore listing venue. The political question is whether the Hong Kong government treats the listed-market weakness as a symptom to manage or as a transition to accelerate. So far, the policy signal — Connect-scheme expansion, biotech-friendly listing rules, family-office tax incentives — points to acceleration.

What remains uncertain

Two things are genuinely unresolved in the source material. First, the SFC's AUM number, while a record, does not yet show the composition of the growth — how much is mainland family office, how much is sovereign, how much is recycled Hong Kong retail. That composition will determine whether the record is durable or fragile. Second, the Takeda–Insilico deal is a headline-value announcement; the realised value depends on milestones that may or may not be hit. Milestone-driven biotech deals routinely deliver 20–40% of headline value in cash, with the rest contingent. The SCMP essay is correct to be sceptical about the listed market; it is too quick to extrapolate from there to a verdict on the city as a financial centre.

Monexus is publishing this piece against a Reuters wire of SFC data, an SCMP opinion essay, and a Nikkei Asia report on Takeda–Insilico. Where the wire data and the opinion diverge, we have foregrounded both — the listed market's weakness is real, and the underlying intermediation's strength is also real.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• http://reut.rs/3TfvvKA
• https://t.me/SCMPNews
• https://t.me/reuters
• https://t.me/polymarket
• https://t.me/nikkeiasia
• https://en.wikipedia.org/wiki/Hang_Seng_Index